SCHEMBL24089316

SCHEMBL24089316

Cc1ccc2[nH]ncc2c1C(C)(C)Cn1ncc2c(C(C)(C)C)c(C)ccc21

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22967880 0.92 NOS1 (0.32) —
SCHEMBL17030759 0.79 IDO1 (0.41) —
SCHEMBL21938210 0.75 IDO1 (0.38) —
SCHEMBL22924097 0.72 CYP17A1 (0.30) —
SCHEMBL24944418 0.72 — —
SCHEMBL24285781 0.71 IDO1 (0.34) —
SCHEMBL22967842 0.69 MAPT (0.34) —
SCHEMBL22924093 0.69 — —
SCHEMBL18408609 0.68 — —
SCHEMBL24089313 0.68 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210380595-A1 2-(2-ACRYLOYL-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-6-(1H-INDAZOL-4-YL)-BENZONITRILE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF G12C MUTANT KRAS PROTEIN FOR INHIBITING TUMOR METASTASIS ARAXES PHARMA LLC (US) 2021-12-09 — — US disclosed
Send feedback